CPHI Milan 2
CPHI Milan newsletter
PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical
Volume 14 issue 3

Handling with Care: Aseptic Dip Coating for Osteoporosis Treatment

Kindeva Drug Delivery is a contract development and manufacturing organisation (CDMO) specialising in complex drug formulation and delivery. Seeking to scale its pro...
Continue Reading →
News

PCI Pharma Services Announces Multi-Million Dollar Expansion to UK Manufacturing Facility to Meet Growing Demand for Global High Potent Manufacturing Services Supporting Oncology Treatments

New facilities offer innovative equipment and increased capacity to bring highly potent oncology therapies to market PHILADELPHIA – July 27, 2022 – PCI Pharma Ser...
Continue Reading →
Volume 13 Issue 3

Current Trends in Formulation Development and Implications for Drug Delivery Devices

The market for parenteral drug-device combination products has been evolving over the last 15–20 years, developing innovation both on formulation and device design f...
Continue Reading →
News

ChargePoint Technology appoints business development manager for EMEIA

Andrew McCreadie Powder containment and aseptic transfer valve specialist, ChargePoint Technology has appointed Andrew McCreadie as their new business development...
Continue Reading →
News

Cambrex to Acquire Halo Pharma, Adding Drug Development and Finished Dosage Capabilities to Global API Manufacturing Network

Cambrex Corporation (NYSE: CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced it has ente...
Continue Reading →
News

WuXi STA and Antengene Sign Development and Manufacturing Agreement

STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Antengene Corporation, a biopharmaceutical company, recently announced a strateg...
Continue Reading →
News

FDA Announces Policies to Facilitate Development of Generic Drugs

Commissioner outlines new policies for drugs that have Risk Evaluation and Mitigation Strategy (REMS) requirements. In a recent statement, US Food and Drug Administr...
Continue Reading →
News

LABCORP EXPANDS DRUG DEVELOPMENT SOLUTIONS WITH ACQUISITION OF SCIFORMIX

Sciformix extends Covance’s pharmacovigilance capabilities for post-approval safety solutions LabCorp® (NYSE: LH), a leading global life sciences company, announced ...
Continue Reading →
News

International Conference on Pharmaceutical Research and Development

International Conference on Pharmaceutical Research and Development (Pharma Research 2018) scheduled to be held during June 06-07, 2018, Philadel...
Continue Reading →
News

Copley Scientific introduces new test equipment for generic product development at RDD 2018

Albuterol Inhalation Aerosol Sampling Apparatus for delivered dose uniformity (DDU) testing as described in the proposed USP monograph Generic developers looking...
Continue Reading →

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026